InsidersTradesSigma
Total declarations
Company
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
6
Disclosed sells
0
T+90 hit rate
83%
T+90 mean return
+22.5%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Patrick ALEXANDRE, Management Board Chairman. Director active across 1 company, notably CROSSJECT. Aggregated, 6 filings have been logged. Breakdown: 6 buys · 0 sell. Total volume traded: €187k. History available since 17 October 2022. The latest transaction was disclosed on 19 February 2025 (Acquisition d'actions gratuites). Regulator: AMF. The full history is accessible without signup.
Declarations6 total
300,000 shares0ActionEuronext Growth Paris2025DD1021709
Ideal exit: 16 Nov 2025 (T+270)
130,000 shares0ActionEuronext Growth Paris2024DD982585
Ideal exit: 17 Mar 2025 (T+270)
5,536 shares@ €1.8485.5% of flowActionEuronext Growth Paris2024DD970037
Ideal exit: 3 Mar 2025 (T+270)
173,499 shares@ €0.991591.8% of flowActionEuronext Growth Paris2022DD874066
Ideal exit: 26 Aug 2023 (T+270)
1,938 shares@ €2.702.8% of flowActionEuronext Growth Paris2022DD868925
Ideal exit: 25 Jul 2023 (T+270)
9,000 shares0ActionHors plateforme de négociation2022DD868930
Ideal exit: 14 Jul 2023 (T+270)
6 of 6 declarations
About Patrick ALEXANDRE
Patrick ALEXANDRE is the founder and long-standing chief executive of CROSSJECT, where he currently serves as Chairman of the Management Board and CEO. A graduate of SUPÉLEC, he first built his career as an engineer and R&D leader in heavy industry, managing research and development teams in the steel sector for more than ten years. He then spent over fifteen years in the pharmaceutical industry, giving him a distinctive combination of industrial, technological and healthcare expertise. Before founding CROSSJECT, he worked at Arcelor and later at Laboratoires Fournier, where he refined a disciplined approach to innovation, quality and large-scale industrial execution. His most notable contribution is the conception and development, beginning in 1997 at Laboratoires Fournier, of the needle-free injection technology that would later become the foundation of CROSSJECT when the company was created in 2001. That strategic asset led to ZENEO®, the company’s needle-free auto-injector platform focused on emergency treatments. Patrick ALEXANDRE also held general management responsibilities before being appointed Chairman of the Management Board in 2012, gradually shaping the company’s governance around a long-term innovation strategy. Under his leadership, CROSSJECT has positioned itself as a specialty pharmaceutical company focused on self-administered emergency products, with an explicit international ambition. In 2025, his mandate was renewed by the Supervisory Board as part of a streamlined Executive Board designed to concentrate on the final FDA registration steps for ZEPIZURE®, a key program in the group’s transition toward direct commercialization in the United States. This underscores his focus on industrial delivery, regulatory progress and medium-term value creation.
